This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

IBM, JPMorgan, Procter & Gamble: Dow Movers

NEW YORK (TheStreet) -- Stocks finished Thursday on a positive note after better-than-expected jobless claims.

The Dow Jones Industrial Average rose 46.02 points, or 0.36%, to 12,984.69. The S&P 500 increased 5.8 points to 1,363.46 and the Nasdaq Composite had a gain of 23.81 points to 2,956.98.

Breadth within the Dow was positive with 20 of the index's 30 components posting gains.

The biggest percentage advancers among the blue chips wereIBM (IBM), JPMorgan Chase (JPM) and Procter & Gamble (PG).

Procter & Gamble shares increased 3.07% to $66.42. The company said it anticipates cutting about 5,700 jobs in the next year and a half to cut costs, according to The Associated Press. Procter & Gamble expects to save about $10 billion by June, 2016, the AP reported.

TheStreet Ratings gives Procter & Gamble an A- grade with a buy rating and $75.31 price target.

Shares of JPMorgan rose 1.1% to $38.49. The move came despite news thatbank fees could be threatened by the Consumer Financial Protection Bureau, which is probing overdraft practices.

TheStreet Ratings gives JPMorgan a B grade with a buy rating and $43.89 price target.

Shares of IBM rose 1.93% to $197.61. The stock hit a 52-week high Thursday of $199.23.

TheStreet Ratings gives IBM an A+ grade with a buy rating and a $253.34 price target.

The biggest decliners in the index were HP (HPQ) and Pfizer (PFE).

HP shares fell 6.53% to $27.05. The PC and printer maker first-quarter earnings of $1.5 billion, or 73 cents a share, up from year-ago earnings of $239 million, or 12 cents a share, late Wednesday, but gave a weak outlook for the current quarter.

TheStreet Ratings gives HP a C grade and hold rating.

Shares of Pfizer dropped 1.54% to $21.03. The pharmaceutical company gets an A- grade with a buy rating and $26.30 price target.

--Written by Alexandra Zendrian in New York.



>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to: tips@thestreet.com.

>To follow the writer on Twitter, go to Alexandra Zendrian.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,976.11 -107.69 -0.63%
S&P 500 1,978.39 -9.59 -0.48%
NASDAQ 4,440.3530 -31.7550 -0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs